Investigating the effect of ribavirin treatment on genetic mutations in Crimean–Congo haemorrhagic fever virus (CCHFV) through next‐generation sequencing

Crimean–Congo haemorrhagic fever (CCHF) is the most widespread tick‐borne viral haemorrhagic fever affecting humans, and yet a licensed drug against the virus (CCHFV) is still not available. While several studies have suggested the efficacy of ribavirin against CCHFV, current literature remains inco...

Full description

Saved in:
Bibliographic Details
Published in:Journal of medical virology 2023-02, Vol.95 (2), p.e28548-n/a
Main Authors: D'Addiego, Jake, Elaldi, Nazif, Wand, Nadina, Osman, Karen, Bagci, Binnur Koksal, Kennedy, Emma, Pektas, Ayse Nur, Hart, Eilish, Slack, Gillian, Hewson, Roger
Format: Article
Language:English
Subjects:
Antiviral drugs
Crimean hemorrhagic fever
Crimean–Congo haemorrhagic fever virus
Fever
Genomes
Health services
Hemorrhage
Hemorrhagic Fever Virus, Crimean-Congo - drug effects
Hemorrhagic Fever Virus, Crimean-Congo - genetics
Hemorrhagic Fever, Crimean - drug therapy
Hemorrhagic Fever, Crimean - epidemiology
High-Throughput Nucleotide Sequencing
Humans
Mass extinctions
Mutagenesis
Mutation
Ribavirin
Ribavirin - therapeutic use
Species extinction
variant
Viremia
Virology
Viruses
whole genome next‐generation sequencing
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Crimean–Congo haemorrhagic fever (CCHF) is the most widespread tick‐borne viral haemorrhagic fever affecting humans, and yet a licensed drug against the virus (CCHFV) is still not available. While several studies have suggested the efficacy of ribavirin against CCHFV, current literature remains inconclusive. In this study, we have utilised next‐generation sequencing to investigate the mutagenic effect of ribavirin on the CCHFV genome during clinical disease. Samples collected from CCHF patients receiving ribavirin treatment or supportive care only at Sivas Cumhuriyet University Hospital, Turkey, were analysed. By comparing the frequency of mutations in each group, we found little evidence of an overall mutagenic effect. This suggests that ribavirin, administered at the acute stages of CCHFV infection (at the World Health Organization‐recommended dose) is unable to induce lethal mutagenesis that would cause an extinction event in the CCHFV population and reduce viremia.
ISSN:0146-6615
1096-9071
DOI:10.1002/jmv.28548